Exhibit 10.1
REGENERX BIOPHARMACEUTICALS, INC.
CONVERTIBLE NOTE AND WARRANT PURCHASE AGREEMENT
February [__], 2019
Table of Contents
| Page | ||
| SECTION 1. | DEFINITIONS | 1 |
| SECTION 2. | ISSUANCE AND SALE OF THE SECURITIES | 4 |
| 2.1 | 1st Funding | 4 |
| 2.2 | 2nd Funding | 4 |
| SECTION 3. | THE FUNDING | 4 |
| 3.1 | Funding | 4 |
| 3.2 | Deliveries by the Company | 5 |
| 3.3 | Deliveries by the Investor | 5 |
| SECTION 4. | REPRESENTATIONS, WARRANTIES AND COVENANTS | 6 |
| 4.1 | Representations and Warranties of the Company | 6 |
| 4.2 | Representations and Warranties of the Investor | 8 |
| SECTION 5. | CONDITIONS TO FUNDING | 9 |
| 5.1 | Conditions to Funding by the Investor | 9 |
| 5.2 | Conditions to Funding by the Company | 10 |
| SECTION 6. | MISCELLANEOUS | 11 |
| 6.1 | Waivers and Amendments | 11 |
| 6.2 | Costs and Expenses | 11 |
| 6.3 | Remedies Cumulative | 11 |
| 6.4 | Remedies Not Waived | 11 |
| 6.5 | Entire Agreement | 12 |
| 6.6 | Specific Performance | 12 |
| 6.7 | Governing Law | 12 |
| 6.8 | Notices | 12 |
| 6.9 | Counterparts | 13 |
| 6.10 | Successors and Assigns | 13 |
| 6.11 | Third Parties | 13 |
| 6.12 | Schedules and Exhibits | 13 |
| 6.13 | Headings | 13 |
| -i- |
CONVERTIBLE NOTE AND WARRANT PURCHASE AGREEMENT
THIS CONVERTIBLE NOTE AND WARRANT PURCHASE AGREEMENT (this “Agreement”), dated as of February 26, 2019, is entered into by and between RegeneRx Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and _________, a resident of ________ (the “Investor”).
RECITALS
Whereas, the Company has authorized the sale and issuance of (i) convertible promissory notes in the form attached hereto asExhibit A (the “Notes” and, the securities issuable on conversion of such Notes, the “Conversion Shares”) and (ii) warrants, in substantially the form attached hereto asExhibit B (the “Warrant”), to purchase shares of the Company’s Common Stock (the “Warrant Shares” and, along with the Conversion Shares, the Warrants and the Notes, the “Securities”), pursuant to the terms of a series of Agreements on substantially identical terms to this Agreement;
Whereas, the Company desires to fund the Notes in two tranches, the initial tranche to be funded on or before February 28, 2019, and with the second tranche to be funded after the first patient has been enrolled in the ARISE-3 Phase 3 Clinical Trial, on the terms and conditions set forth herein; and
Whereas, the Investor desires to purchase the Securities on the terms and conditions set forth herein; and
Whereas, the Company desires to issue and sell the Securities to the Investor on the terms and conditions set forth herein.
Agreement
Now, Therefore, in consideration of the foregoing recitals and the mutual promises, representations, warranties, and covenants hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:
SECTION 1. DEFINITIONS
The following terms when used in this Agreement shall have the following respective meanings:
“1st Funding” has the meaning set forth in Section 3.1 hereof.
“1st Funding Date” has the meaning set forth in Section 3.1 hereof.
“1st Purchase Price” has the meaning set forth in Section 2.1 hereof.
“2nd Funding” has the meaning set forth in Section 3.1 hereof.
| 1 |
“2nd Funding Date” has the meaning set forth in Section 3.1 hereof.
“2nd Purchase Price” has the meaning set forth in Section 2.2 hereof.
“Agreement” has the meaning set forth in the Preamble.
“Applicable Laws” has the meaning set forth in Section 4.1(f) hereof.
“ARISE-2” means the Phase 2/3 clinical trial using RGN-259 to treat dry eye syndrome, which was sponsored by ReGenTree and managed by Ora, Inc., and the results of which were reported by the Company in October 2017.
“ARISE-3 Phase 3 Clinical Trial” means the Phase 3 clinical trial using RGN-259 to treat dry eye syndrome, which is sponsored by ReGenTree, in order to confirm the results of ARISE-2.
“Board of Directors” means the Board of Directors of the Company.
“Capital Stock” means (i) with respect to any Person that is a corporation, any and all shares, interests or equivalents in capital stock (whether voting or nonvoting and whether common or preferred) of such corporation and (ii) with respect to any Person that is not a corporation, any and all partnership, membership, limited liability company or other equity interests of such Person; and in each case, any and all warrants, rights or options to purchase any of the foregoing.
“Certificate of Incorporation” means the Certificate of Incorporation of the Company, as in effect and on file with the Secretary of State of the State of Delaware on the date of this Agreement.
“Common Stock” means the Common Stock of the Company, par value $0.001 per share.
“Company” has the meaning set forth in the Preamble.
“Conversion Shares” has the meaning set forth in the Preamble.
“Exchange Act” means the Securities Exchange Act of 1934, as amended.
“Governmental Authority” means the United States, any state, county or municipality, the government of any foreign country, any subdivision of any of the foregoing or any authority, department, commission, board, bureau, agency, court or instrumentality of any of the foregoing.
“Investor” has the meaning set forth in the Preamble.
“Knowledge of the Company,” including the terms “Know,” “Known” and other derivatives thereof, means, with respect to the Company, the actual knowledge, after reasonable investigation, of any Responsible Officer.
| 2 |
“Lien” means any mortgage, lien, pledge, security interest, easement, conditional sale or other title retention agreement or other encumbrance of any kind except for liens relating to taxes that have accrued but are not yet payable which do not have a Material Adverse Effect.
“Material Adverse Effect” means a material adverse effect upon (i) the condition (financial or otherwise), operations, business, properties or assets of the Company, (ii) the ability of the Company to perform its obligations under this Agreement or any of the other agreements or documents contemplated hereby to which it is a party or (iii) the legality, validity or enforceability of this Agreement or any of the other agreements or documents contemplated hereby or the rights and remedies of the Investor and the other parties hereunder and thereunder.
“Material Agreements” has the meaning set forth in Section 4.1(e) hereof.
“Notes” has the meaning set forth in the Preamble.
“Parties” refers collectively to the Company and the Investor.
“Person” means an individual, corporation, partnership, joint venture, trust, unincorporated organization, or Governmental Authority.
“ReGenTree” means ReGenTree LLC, a Delaware limited liability company.
“Regulation D” has the meaning set forth in Section 4.2(c) hereof.
“Responsible Officer” means, with respect to the Company, the President and Chief Executive Officer or the Chairman of the Board of Directors.
“Returns” has the meaning set forth in Section 4.1(i) hereof.
“SEC” means the U.S. Securities and Exchange Commission.
“SEC Reports” has the meaning set forth in Section 4.1(h)(i) hereof.
“Securities” has the meaning set forth in the Preamble.
“Securities Act” means the Securities Act of 1933, as amended.
“Stockholders” has the meaning set forth in Section 4.1(b) hereof.
“Tax” or “Taxes” refers to any and all federal, state, national, local, foreign and other taxes, assessments and other governmental charges, duties, levies, impositions and liabilities relating to taxes, including taxes based upon or measured by gross receipts, income, profits, sales, use and occupation, and value added, ad valorem, transfer, franchise, withholding, payroll, recapture, employment, excise and property taxes, together with all interest, penalties and additions imposed with respect to such amounts and any obligations under any agreements or arrangements with any other person with respect to such amounts and including any liability for taxes of a predecessor entity.
| 3 |
“Warrant” has the meaning set forth in the Preamble.
“Warrant Shares” has the meaning set forth in the Preamble.
SECTION 2. ISSUANCE AND SALE OF THE SECURITIES
2.1 1st Funding
At the 1st Funding, the Company shall issue and sell to the Investor, and such Investor shall purchase, for an aggregate purchase price of $12,500 (the “1st Purchase Price”), from the Company, (i) a Note in the principal amount of the 1st Purchase Price and (ii) a Warrant to purchase 78,125 Warrant Shares at an exercise price of $.18 per share.
2.2 2nd Funding
At the 2nd Funding, the Company shall issue and sell to the Investor, and such Investor shall purchase, for an aggregate purchase price of $12,500 (the “2nd Purchase Price”), from the Company, (i) a Note in the principal amount of the 2nd Purchase Price and (ii) a Warrant to purchase 78,125 Warrant Shares at an exercise price of $.18 per share.
SECTION 3. THE FUNDING
3.1 Funding
The 1st Funding of the issuance and sale of the Securities pursuant to Section 2.1 hereof and certain of the other transactions contemplated hereby (the “1st Funding”) shall take place within one business day following the satisfaction of the conditions specified in Section 5 below, at such time and place as the Parties shall mutually agree (the actual date being referred to herein as the “1st Funding Date”). The Parties agree that the 1st Funding, in the amount of the 1st Purchase Price, may occur electronically by delivery of signatures by electronic, facsimile or other electronic transmission, and delivery of the 1st Purchase Price by wire transfer of immediately available funds to the account designated in writing by the Company.
The 2nd Funding of the issuance and sale of the Securities pursuant to Section 2.2 hereof and certain of the other transactions contemplated hereby (the “2nd Funding”), in the amount of the 2nd Purchase Price, shall take place within three business day following (i) the satisfaction of the conditions specified in Section 5 below, at such time and place as the Parties shall mutually agree, and (ii) delivery by the Company to the Investor of formal notice, including any additional documentation reasonably requested by the Investor related thereto, that the first patient has been enrolled in the ARISE-3 Phase 3 Clinical Trial (the actual date being referred to herein as the “2nd Funding Date”).
| 4 |
3.2 Deliveries by the Company
At the 1st Funding, the Company shall deliver, or cause to be delivered, to the Investor the following items:
(a) A Note in the principal amount of the 1st Purchase Price purchased by the Investor hereunder, registered in the name of the Investor and subject to the legends and other restrictions set forth herein;
(b) a Warrant, executed by the Company and registered in the name of the Investor, pursuant to which the Investor shall have the right to acquire the Warrant Shares issuable to the Investor pursuant to Section 2.1 on the terms set forth therein;
(c) a certificate of the Secretary or Assistant Secretary of the Company, in form and substance satisfactory to counsel for the Investor, certifying that attached thereto are true and correct copies of (i) the Certificate of Incorporation and bylaws of the Company (including, in each case, all amendments and modifications to the date of such certificate), and (ii) resolutions duly and validly adopted by the Board of Directors authorizing the allotment and issuance of the Securities to the Investor, execution and delivery of this Agreement and the consummation of the transactions contemplated hereby; and
(d) a certificate of the Secretary or Assistant Secretary of the Company, in form and substance satisfactory to counsel for the Investor, certifying that the conditions set forth in Section 5.1(a) and (c) have been satisfied.
At the 2nd Funding, the Company shall deliver or cause to be delivered to the Investor the following items:
(a) A Note in the principal amount of the 2nd Purchase Price purchased by the Investor hereunder, registered in the name of the Investor and subject to the legends and other restrictions set forth herein;
(b) a Warrant, executed by the Company and registered in the name of the Investor, pursuant to which the Investor shall have the right to acquire the Warrant Shares issuable to the Investor pursuant to Section 2.2 on the terms set forth therein; and
(c) a certificate of the Secretary or Assistant Secretary of the Company, in form and substance satisfactory to counsel for the Investor, certifying that the conditions set forth in Section 5.3(a), (c) and (d) have been satisfied.
3.3 Deliveries by the Investor
At the 1st Funding, the Investor shall deliver or cause to be delivered to the Company the following items:
(a) payment of the 1st Purchase Price in immediately available funds by wire transfer to an account designated in writing by the Company prior to the 1st Funding Date; and
| 5 |
(b) a fully completed and duly executed Accredited Investor Certification in the form attached hereto asExhibit C.
At the 2ndFunding, the Investor shall deliver or cause to be delivered to the Company the following items:
(a) payment of the 2nd Purchase Price in immediately available funds by wire transfer to an account designated in writing by the Company prior to the 2nd Funding Date; and
(b) a fully completed and duly executed Accredited Investor Certification in the form attached hereto asExhibit C.
SECTION 4. REPRESENTATIONS, WARRANTIES AND COVENANTS
4.1 Representations and Warranties of the Company
In order to induce the Investor to purchase the Securities it is purchasing hereunder, the Company represents and warrants to the Investor as of the date hereof that:
(a) Organization and Standing. The Company is duly incorporated and validly existing under the laws of the State of Delaware and has all requisite corporate power and authority to own or lease its properties and assets and to conduct its business as it is presently being conducted.
(b) Capitalization. Immediately subsequent to the consummation of the transactions contemplated by this Agreement, the authorized Capital Stock of the Company shall be as set forth onSchedule 4.1(b) hereto. The outstanding shares of Capital Stock are all duly and validly authorized and issued, fully paid and nonassessable, and based in part on the representations of the stockholders of the Company (the “Stockholders”) made in connection with the issuance thereof, were issued in compliance with all applicable federal and state securities laws.
(c) Capacity of the Company; Consents; Execution of Agreements. The Company has all requisite power, authority and capacity to enter into this Agreement and to perform the transactions and obligations to be performed by it hereunder. The execution and delivery of this Agreement and any agreements contemplated hereby by the Company, and the performance by the Company of the transactions and obligations contemplated hereby and thereby, including, without limitation, the issuance and delivery of the Securities to the Investor, has been duly authorized by all requisite action of the Company and Stockholders. This Agreement has been duly executed and delivered by a duly authorized officer of the Company and constitutes a valid and legally binding agreement of the Company, enforceable in accordance with its respective terms, except as enforcement thereof may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws of the United States (both state and federal), affecting the enforcement of creditors’ rights or remedies in general and general equity principles. The Company is not required to obtain the approval of its stockholders or any approvals under applicable state securities laws or stock exchange listing rules in connection with the execution and delivery of this Agreement and the transactions contemplated hereby.
| 6 |
(d) Status of the Conversion Shares and Warrant Shares; Reservation of Common Stock. The Conversion Shares and Warrant Shares to be issued and purchased hereunder, when issued by the Company to the Investor and paid for by the Investor pursuant to the terms of this Agreement, the Note and Warrant, respectively, will (i) be duly authorized, validly issued, fully paid and nonassessable, (ii) based on the Investor’s representations in Section 4.2, have been issued in compliance with all applicable United States federal and state securities laws, and (iii) be free and clear of all Liens. The Company has available sufficient shares of Common Stock for issuance pursuant to the terms of this Agreement.
(e) Conflicts; Defaults. The execution and delivery of this Agreement by the Company and the performance by the Company of the transactions and obligations contemplated hereby to be performed by it will not (i) materially violate, conflict with, or constitute a default under any of the terms or provisions of, the Certificate of Incorporation, the bylaws, or any provisions of, or result in the acceleration of any obligation under, any material contract, note, debt instrument, security agreement, or other instrument to which the Company is a party or by which the Company, or any of their assets is bound (collectively, the “Material Agreements”); (ii) result in the creation or imposition of any Liens or claims upon the Company’s assets or upon the Company’s Common Stock; (iii) assuming the accuracy of the Investor’s representations in Section 4.2, constitute a material violation of any law, statute, judgment, decree, order, rule, or regulation of a Governmental Authority applicable to the Company; or (iv) constitute an event which, after notice or lapse of time or both, would result in any of the foregoing. The Company is not presently in violation of its Certificate of Incorporation or bylaws.
(f) Compliance with Laws. The Company is not in violation of, nor do any of its respective operations violate in any respect, any statute, law, or regulation of any Governmental Authority applicable to the Company (“Applicable Laws”), which violation would have a Material Adverse Effect.
(g) Litigation. As of the date hereof: (i) the Company is not subject to any order of, or written agreement or memorandum of understanding with, any Governmental Authority which would have a Material Adverse Effect; (ii) there are no material actions, suits, claims, investigations, or proceedings pending at law or in equity or before or by any Governmental Authority, or, to the Knowledge of the Company, threatened, against the Company or any of its assets or properties or the transactions contemplated by this Agreement, and to the Knowledge of the Company, there exist no facts or circumstances which reasonably could be anticipated to result in any such action, suit, claim, investigation, or proceeding; and (iii) no Person has asserted, and, to the Knowledge of the Company, no Person has a valid basis upon which to assert, any claims against the Company that would materially adversely affect the transactions contemplated by this Agreement or result in or form the basis of any such action, suit, claim, investigation or proceeding. There is no material action, suit, proceeding or investigation by the Company currently pending or which the Company intends to initiate.
| 7 |
(h) Securities Laws.
(i) The Company has filed all forms, reports and documents with the SEC required to be filed by it pursuant to the federal securities laws and the SEC rules and regulations thereunder, all of which complied in all material respects with all applicable requirements of the Securities Act and the Exchange Act (collectively, the “SEC Reports”). None of the SEC Reports, including, without limitation, any financial statements or schedules included therein, at the time filed (or if amended or superseded by a filing prior to the date of this Agreement, then on the date of such filing) contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of circumstances under which they were made, not misleading.
(ii) Based on the Investor’s representations in Section 4.2, no consent, authorization, approval, permit, or order of or filing with any Governmental Authority is required in order for the Company to execute and deliver this Agreement or in order for the Company to offer, issue, sell, or deliver the Securities. Based in part on the representations of the Investor and under the circumstances contemplated hereby and under current laws and regulations, the offer, issuance, sale and delivery of the Securities to the Investor is exempt from the registration requirements of the Securities Act.
(i) Taxes. The Company has timely filed or caused to be filed with the appropriate taxing authority all federal, state, national, local and foreign returns, estimates, information statements and reports (“Returns”) relating to Taxes required to be filed by the Company on or prior to the 1st Funding Date or the 2nd Funding Date, as applicable. The Returns have accurately reflected in all material respects and will accurately reflect in all material respects all liability for Taxes of the Company for the periods covered thereby.
4.2 Representations and Warranties of the Investor
The Investor hereby represents and warrants to the Company that as of the date hereof:
(a) Investment Intent. The Securities to be purchased by the Investor hereunder are being purchased for its own account and not with the view to, or for resale in connection with, any distribution or public offering thereof within the meaning of the Securities Act. The Investor understands that the Securities have not been registered under the Securities Act by reason of their issuance in transactions exempt from the registration and prospectus delivery requirements of the Securities Act pursuant to Section 4(a)(2) thereof. The Investor further understands that the certificates representing the Conversion Shares and any Warrant Shares that may be issued pursuant to the conversion of the Note and exercise of the Warrant, respectively, will bear the following legend and the Investor agrees that it will hold such shares subject thereto:
“THESE SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE“SECURITIES ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN COMPLIANCE WITH APPLICABLE STATE SECURITIES LAWS OR BLUE SKY LAWS.”
| 8 |
(b) Capacity of the Investor; Execution of Agreement. The Investor has all requisite power, authority and capacity to enter into this Agreement, deliver the 1st Purchase Price and the 2nd Purchase Price, and to perform the transactions and obligations to be performed by it hereunder. This Agreement has been duly authorized, executed and delivered by them and constitutes its valid and legally binding obligation, enforceable in accordance with its terms, except as enforcement thereof may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws, both state and federal, affecting the enforcement of creditors’ rights or remedies in general from time to time in effect and the exercise by courts of equity powers or their application of principles of public policy.
(c) Accredited Investor. The Investor is an “accredited investor” as defined in Rule 501(a) of Regulation D promulgated under the Securities Act (“Regulation D”).
(d) Suitability and Sophistication. (i) The Investor has such knowledge and experience in financial and business matters that it is capable of independently evaluating the risks and merits of purchasing the Securities; (ii) the Investor has independently evaluated the risks and merits of purchasing the Securities and has independently determined that the Securities are a suitable investment for it; and (iii) the Investor has sufficient financial resources to bear the loss of their entire investment in the Securities.
(e) Receipt of Information. The Investor believes, after due inquiry and investigation, that it has received all of the information that it considers necessary or appropriate for deciding whether to purchase the Securities. The Investor further represents that it has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of the Securities and the business, properties, prospects and financial condition of the Company and to obtain additional information (to the extent the Company possessed such information or could acquire it without unreasonable effort or expense) necessary to verify the accuracy of any information furnished to the Investor. The foregoing, however, does not limit or modify the representations and warranties of the Company in Section 4 of this Agreement or the right of the Investor to rely thereon.
(f) Independent Existence. The Investor was not formed for the specific purpose of purchasing the Securities.
SECTION 5. CONDITIONS TO FUNDING
5.1 Conditions to 1st Funding by the Investor
The obligations of the Investor to consummate the purchase of the Securities pursuant to Section 2 hereof and certain of the transactions contemplated by this Agreement are subject to the satisfaction on or prior to the 1st Closing Date of the following conditions, any of which may be waived in whole or in part in writing by the Investor:
| 9 |
(a) all representations and warranties of the Company contained in this Agreement shall be true and correct as of the date of this Agreement and as of the 1st Funding Date as though made anew as of such date (unless another date is specified);
(b) the Company shall have delivered to the Investor the items required by Section 3.2 of this Agreement;
(c) the Company shall have performed and complied with all agreements and conditions required by this Agreement to be performed and complied with by it prior to or as of the 1st Funding Date; and
(d) all pre-issuance registrations, qualifications, permits and approvals required, if any, under applicable state securities laws or stock exchange listing rules for the lawful execution and delivery of this Agreement and the offer, sale, issuance and delivery of the Securities shall have been obtained.
5.2 Conditions to Funding by the Company
The obligations of the Company to consummate the issuance and sale of the Securities pursuant to Section 2.1 hereof and certain of the transactions contemplated by this Agreement are subject to the satisfaction on or prior to the 1st Funding Date of the following conditions, any of which may be waived, in whole or in part, in writing by the Company:
(a) all representations and warranties of the Investor contained in this Agreement shall be true and correct as of the date of this Agreement and as of the 1st Funding Date as though made anew as of such date;
(b) the Investor shall have delivered to the Company the items required by Section 3.3 of this Agreement;
(c) all pre-issuance registrations, qualifications, permits and approvals required, if any, under applicable state securities laws or stock exchange listing rules for the lawful execution and delivery of this Agreement and the offer, sale, issuance and delivery of the Securities shall have been obtained; and
(d) the Investor shall have performed and complied with all agreements and conditions required by this Agreement to be performed and complied with by it prior to or as of the 1st Funding Date.
5.3 Conditions to 2nd Funding by the Investor
The obligations of the Investor to consummate the issuance and sale of the Securities pursuant to Section 2.2 hereof and the 2nd Funding contemplated by this Agreement are subject to the satisfaction on or prior to the 2nd Funding Date of the following conditions, any of which may be waived, in whole or in part, in writing by the Investor:
(a) all representations and warranties of the Company contained in this Agreement shall be true and correct as of the date of this Agreement and as of the 2nd Funding Date as though made anew as of such date (unless another date is specified);
| 10 |
(b) the Company shall have delivered to the Investor the items required by Section 3.3 of this Agreement;
(c) the Company shall have performed and complied with all agreements and conditions required by this Agreement to be performed and complied with by it prior to or as of the 1st Funding Date; and
(d) all relevant documentation as may be reasonably requested by the Investor shall have been delivered by the Company to the Investor demonstrating that the first patient has been enrolled in the ARISE-3 Phase 3 Clinical Trial.
SECTION 6. MISCELLANEOUS
6.1 Waivers and Amendments
This Agreement may be amended or modified in whole or in part only by a writing which makes reference to this Agreement that is executed by the Investor and the Company. The obligations of any Party hereunder may be waived (either generally or in a particular instance and either retroactively or prospectively) only with the written consent of the party claimed to have given the waiver; provided, however, that any waiver by any party of any violation of, breach of, or default under any provision of this Agreement or any other agreement provided for herein shall not be construed as, or constitute, a continuing waiver of such provision, or waiver of any other violation of, breach of or default under any other provision of this Agreement or any other agreement provided for herein.
6.2 Costs and Expenses
Each party agrees to pay its own costs and expenses in connection with the preparation, execution and delivery of this Agreement and other instruments and documents to be delivered hereunder and thereunder.
6.3 Remedies Cumulative
No specific right, power, or remedy conferred by this Agreement shall be exclusive, and each such right, power, or remedy shall be cumulative and in addition to every other right, power, or remedy, whether conferred hereby or by any security of the Company or now or hereafter available, at law or in equity, by statute or otherwise.
6.4 Remedies Not Waived
No course of dealing between the Company and the Investor, and no delay in exercising any right, power, or remedy conferred hereby or by any security issued by the Company, or now or hereafter available at law or in equity, by statute or otherwise, shall operate as a waiver of or otherwise prejudice any such right, power, or remedy.
| 11 |
6.5 Entire Agreement
This Agreement and the other agreements and instruments expressly provided for herein, together set forth the entire understanding of the parties hereto and supersede in their entirety all prior contracts, agreements, arrangements, communications, discussions, representations and warranties, whether oral or written, among the parties with respect to the subject matter hereof.
6.6 Specific Performance
The Company and the Investor acknowledge and agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with the specific terms hereof or were otherwise breached. It is accordingly agreed that, to the fullest extent permitted by law or equity, each of the parties shall be entitled to an injunction or injunctions to prevent or cure breaches of the provisions of this Agreement and to enforce specifically the terms and provisions hereof, this being in addition to any other remedy to which the parties may be entitled by law or equity.
6.7 Governing Law
This Agreement shall in all respects be governed by and construed in accordance with the internal substantive laws of the State of Delaware without giving effect to the principles of conflicts of law thereof.
6.8 Notices
Any notice, request or other communication required or permitted hereunder shall be in writing and be deemed to have been duly given (a) when personally delivered or sent by facsimile transmission (the receipt of which is confirmed in writing), (b) one business day after being sent by a nationally recognized overnight courier service or (c) three business days after being sent by registered or certified mail, return receipt requested, postage prepaid, to the parties at their respective addresses set forth below.
If to the Company:
RegeneRx Biopharmaceuticals, Inc.
15245 Shady Grove Road
Suite 470
Rockville, MD 20850
Attention: J.J. Finkelstein
Facsimile: 301-208-9194
With a copy, which shall not constitute notice, to:
Avisen Legal P.A.
901 Marquette Avenue Suite 1675
Minneapolis, MN 55402
Attention: Todd Taylor
ttaylor@avisenlegal.com
If to the Investor:
| 12 |
To the address set forth below the Investor’s name on the signature page of this Agreement.
Any party by written notice to the others may change the address or the persons to whom notices or copies thereof shall be directed.
6.9 Counterparts
This Agreement may be executed in counterparts (including by facsimile or other electronic transmission), each of which shall be deemed to be an original, and all of which together shall constitute one and the same instrument.
6.10 Successors and Assigns
This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and assigns.
6.11 Third Parties
Nothing expressed or implied in this Agreement is intended, or shall be construed, to confer upon or give any Person other than the parties hereto any rights or remedies under or by reason of this Agreement.
6.12 Schedules and Exhibits
The schedules and exhibits attached to this Agreement are incorporated herein and shall be part of this Agreement for all purposes.
6.13 Headings
The headings in this Agreement are solely for convenience of reference and shall not be given any effect in the construction or interpretation of this Agreement.
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
| 13 |
IN WITNESS WHEREOF, the parties have duly executed, or have caused their duly authorized officer or representative to execute, this Securities Purchase Agreement as of the date first above written.
REGENERX BIOPHARMACEUTICALS, INC.
| By: | ||
| Name: | ||
| Title: | ||
IN WITNESS WHEREOF, the parties have duly executed, or have caused their duly authorized officer or representative to execute, this Securities Purchase Agreement as of the date first above written.
Name of Purchaser:
Signature of Authorized Signatory of Purchaser: _________________________________
Name of Authorized Signatory:
Title of Authorized Signatory:
Facsimile Number of Authorized Signatory:
Address for Notice of Purchaser:
Address for Delivery of Securities for Purchaser (if not same as address for notice):
__________________//_______________
Exhibit A
FORM OF NOTE
[ATTACHED]
ExhibitB
FORM OF WARRANT
[ATTACHED]
Exhibit C
ACCREDITED INVESTOR CERTIFICATION
The undersigned represents and warrants to RegeneRx Biopharmaceuticals, Inc. (the “Company”) that the undersigned fits within each category marked below, and that for any category marked, he, she or it has truthfully set forth any description required as provided for below. ALL INFORMATION WILL BE KEPT STRICTLY CONFIDENTIAL. The undersigned agrees to furnish any additional information that the Company deems necessary in order to verify the answers set forth below.
(PLEASE MARK EACH CATEGORY APPLICABLE TO YOU)
| ¨ | The undersigned is an individual (not a partnership, corporation, etc.) whose individual net worth, or joint net worth with his or her spouse, presently exceeds $1,000,000. |
Explanation. In calculating net worth you may include equity in personal property and real estate, including your principal residence, cash, short-term investments, stock and securities. Equity in personal property and real estate should be based on the fair market value of such property minus debt secured by such property.
| ¨ | The undersigned is an individual (not a partnership, corporation, etc.) who had an income in excess of $200,000 in each of the two most recent years, or joint income with his or her spouse in excess of $300,000 in each of those years (in each case, including foreign income, tax exempt income and full amount of capital gains and losses, but excluding any income of other family members and any unrealized capital appreciation), and has a reasonable expectation of reaching the same income level in the current year. |
| ¨ | The undersigned is a director or executive officer of the Company. |
| ¨ | The undersigned is either: (a) a bank as defined in Section 3(a)(2) of the Securities Act of 1933, as amended (the “Act”); (b) a savings and loan association or other institution as defined in Section 3(a)(5)(A) of the Act, whether acting in its individual or fiduciary capacity; (c) a broker dealer registered pursuant to Section 15 of the Securities Exchange Act of 1934; (d) an insurance company as defined in Section 2(13) of the Act; (e) an investment company registered under the Investment Company Act of 1940 or a business development company as defined in Section 2(a)(48) of the Act; (f) a small business investment company licensed by the U.S. Small Business Administration under Section 301(c) or (d) of the Small Business Investment Act of 1958; (g) a plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political subdivisions, for the benefit of its employees, if such a plan has total assets in excess of $5,000,000; or (h) an employee benefit plan within the meaning of the Employee Retirement Income Security Act of 1974 (“ERISA”), if the investment decision is made by a plan fiduciary, as defined in Section 3(21) of ERISA, which is either a bank, savings and loan association, insurance company or registered investment advisor, or if the employee benefit plan has total assets in excess of $5,000,000, or, if a self-directed plan, with investment decisions made solely by persons that are accredited investors, as defined in Rule (501)(a) promulgated under the Act. |
| (describe entity) |
| ¨ | The undersigned is a private business development company as defined in Section 202(a)(22) of the Investment Advisers Act of 1940. |
| (describe entity) |
| ¨ | The undersigned is an organization within the meaning of Section 501(c)(3) of the Internal Revenue Code, a corporation, a business trust, or a partnership, not formed for the specific purpose of acquiring the Securities, with total assets in excess of $5,000,000. |
| (describe entity) |
| ¨ | The undersigned is a trust with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the Securities, whose investments are directed by a “sophisticated person” as described in Rule 506(b)(2)(ii) promulgated under the Act. |
| ¨ | The undersigned is an entity, all the equity owners of which are “accredited investors” within one or more of the above categories.If relying upon this category alone, each equity owner must complete a separate copy of this Certificate. |
| (describe entity) |
| ¨ | The undersigned does not meet the criteria of any of the categories listed above. |
THE UNDERSIGNED UNDERSTANDS THAT THE COMPANY WILL RELY ON THE FOREGOING REPRESENTATIONS TO, AMONG OTHER THINGS, MAINTAIN THE EXEMPTION FOR THE ISSUANCE OF THE SECURITIES FROM THE REQUIREMENT TO REGISTER SUCH SECURITIES UNDER THE ACT.
The answers to the foregoing questions are correctly stated to the best of my knowledge, information and belief. I hereby agree to notify the Company promptly of any changes in the foregoing information.
Dated: ________________
Name of Purchaser:
Signature of Authorized Signatory of Purchaser: _________________________________
Name of Authorized Signatory:
Title of Authorized Signatory: _____________________________________